The Akt and ERK Activation by Platinum-based Chemotherapy in Ovarian Cancer is Associated with Favorable Patient Outcome
Authors:
- 1 November 2009
- journal article
- research article
- Vol. 29 (11) , 4639-4647
Abstract
Aim: To investigate the phosphatidylinositol 3-kinase (PI3K)-Akt and extracellular signal regulated protein kinase (ERK) activation by chemotherapy, and the relationship between the activation of them and patient outcomes. The effect of chemotherapy on the cell proliferation and apoptosis markers and their role in the biology of ovarian cancer were also investigated. Materials and Methods: This study was carried out in a series of 10 ovarian (or tubal) cancer patients whose specimens were obtained before and after chemotherapy. PI3K-Akt and ERK activation were evaluated by immunohistochemical staining for phosphorylated Akt and ERK. Their correlation with patient outcome was investigated by survival curves using the Kaplan-Meier method. Cell proliferation was evaluated by Ki-67 expression using immunofluorescent staining. Apoptosis was examined by caspase-3 and cleaved Poly ADP ribose polymerase (PARP) using immunofluorescent staining. Results: An increase in Akt and ERK phosphorylation after chemotherapy was observed in 5 and 8 patients, respectively out of 10 patients examined. Akt and ERK activation by chemotherapy were associated with a favorable overall survival. In almost all patients, Ki-67 expression was initially high and largely decreased after chemotherapy. An increase in apoptotic marker expression was observed in almost all patients exposed to chemotherapy. Conclusion: Our findings suggest that Akt and ERK activation by chemotherapy may be associated with favorable prognosis.Keywords
This publication has 21 references indexed in Scilit:
- A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexateCancer Gene Therapy, 2008
- Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: Link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expressionGynecologic Oncology, 2007
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancerOncogene, 2007
- Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancerVirchows Archiv, 2007
- Management of Platinum-Sensitive Recurrent Ovarian CancerSeminars in Oncology, 2006
- Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancerBritish Journal of Cancer, 2005
- Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERKOncogene, 2004
- Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusionsGynecologic Oncology, 2003
- Cisplatin-induced activation of the EGF receptorOncogene, 2002
- Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to PaclitaxelJournal of Biological Chemistry, 2002